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To assess the impact of the genetic variation in toll-like receptors (TLRs) on outcome after allogeneic mye-
loablative conditioning hematopoietic cell transplantation (HCT), we investigated 29 single nucleotide poly-
morphisms across 10 TLRs in 816 patients and donors. Only donor genotype of TLR8 rs3764879, which is located
on the X chromosome, was signiﬁcantly associated with outcome at the Bonferroni-corrected level P  .001.
Male hemizygosity and female homozygosity for the minor allele were signiﬁcantly associated with disease-free
survival (hazard ratio [HR], 1.47 [95% conﬁdence interval {CI}, 1.16 to 1.85]; P ¼ .001). Further analysis stratiﬁed
by donor sex due to confounding by sex was suggestive for associations with overall survival (male donor: HR,
1.41 [95% CI, 1.09 to 1.83], P ¼ .010; female donor: HR, 2.78 [95% CI, 1.43 to 5.41], P ¼ .003), disease-free survival
(male donor: HR, 1.45 [95% CI, 1.12 to 1.87], P ¼ .005; female donor: HR, 2.34 [95% CI, 1.18 to 4.65], P ¼ .015), and
treatment-related mortality (male donor: HR, 1.49 [95% CI, 1.09 to 2.04], P ¼ .012; female donor: HR, 3.12 [95%
CI, 1.44 to 6.74], P ¼ .004). In conclusion, our ﬁndings suggest that the minor allele of TLR8 rs3764879 of the
donor is associated with outcome after myeloablative conditioned allogeneic HCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
After allogeneic hematopoietic cell transplantation (HCT),
both innate and adaptive immune mechanisms are involved
in the immune reactions that result in graft-versus-host dis-
ease (GVHD) and the curative graft-versus-tumor effect [1,2].
Although the importance of HLA matching on outcome after
allogeneic HCT is well recognized [3], the signiﬁcance of ge-
netic variation in immune response genes outside the MHC
system has become increasingly evident [4-8].
The toll-like receptors (TLRs) are germline encoded
pattern recognition receptors that recognize speciﬁcmicrobial
pathogen-associated molecular patterns and endogenous
alarmins [9-12]. TLRs are mainly expressed on antigen-
presenting cells and play a central role in immune surveil-
lance and in the initiation of the inﬂammatory response [9,13].dgments on page 263.
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ty for Blood and Marrow Transplantation.Ten different TLRs (TLR1-10) have been identiﬁed in humans.
After allogeneic HCT, TLRs may not only be involved in the
immune response to infections but also in acute GVHD, where
tissue damage induced by high-dose conditioningmay lead to
amilieuwithample supplyof TLR ligands [14,15]. Furthermore,
TLRs are thought to be involved in the graft-versus-tumor ef-
fect, because administration of TLR agonists has been shown to
induce antitumor immunity and tumor regression in in vivo
tumor models and clinical trials [16-19].
In the setting of allogeneic HCT, TLR genes have been
studied in terms of the impact of their variation on outcome
and susceptibility to infection. Although single nucleotide
polymorphisms (SNPs) in several TLR genes have been
investigated, the most extensively studied are 2 functional
SNPs in TLR4, Thr399Ile and Asp299Gly. These SNPs have
been associated with acute GVHD, invasive aspergillosis, and
hemorrhagic cystitis [20-23].
The objective of the current study is to investigate asso-
ciations between 29 SNPs across 10 TLR genes (Supplemental
Table S1) and outcome in a cohort of 816 patients and donors
undergoing myeloablative conditioning, matched unrelated
Table 1
Transplantation Demographics
Variable Value
Number of patients 816
Number of centers 89
Male patient gender 470 (58)
Median patient age, yr (range) 37 (<1-65)
0-9 yr 61 (7)
10-19 yr 75 (9)
20-29 yr 130 (16)
30-39 yr 206 (25)
40-49 yr 236 (29)
50 yr 108 (13)
Median donor age, yr (range) 36 (18-59)
Sex of donorepatient
Femaleemale 144 (18)
Other combinations 672 (82)
Karnofsky before transplant  90
(only assessable for 789 patients)
627 (79)
CMV serostatus of donorepatient
Negativeenegative 328 (40)
Other combinations 461 (56)
Unknown 27 (3)
Donor previous pregnancies (female only, n ¼ 346)
0 118 (34)
1 50 (14)
2 116 (34)
Unknown 62 (18)
Disease at transplant
AML 126 (15)
ALL 138 (17)
CML 390 (48)
MDS 162 (20)
Disease stage at transplant
Early 651 (80)
Intermediary 72 (9)
Advanced 85 (10)
Other 8 (1)
Graft type
Bone marrow 711 (87)
Peripheral blood stem cells 105 (13)
GVHD prophylaxis
Tacrolimus  other 193 (23)
Cyclosporine þ methotrexate 576 (71)
Other combinations 47 (6)
Use of antithymocyte globulin 75 (9)
Transplantation year
1988-1995 202 (25)
1995-1999 324 (40)
2000-2008 290 (36)
CMV indicates cytomegalovirus.
Values are number of cases with percents in parentheses, unless otherwise
speciﬁed.
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malignancies.
METHODS
The study cohort consisted of 816 donorerecipient pairs with acute
myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic
myeloid leukemia (CML), or myelodysplastic syndrome (MDS) undergoing
myeloablative HCT with bone marrow or granulocyte colony-stimulating
factoremobilized peripheral blood stem cells from 10/10 allele (HLA-A, -B,
-C, -DRB1, and -DQB1) matched unrelated donors. Early-stage disease was
deﬁned as AML and ALL in ﬁrst complete remission, CML in ﬁrst chronic
phase, or MDS with refractory anemia with or without ringed sideroblasts.
Intermediate-stage disease was deﬁned as AML and ALL in second or sub-
sequent complete remission or in ﬁrst relapse or CML in accelerated phase or
greater than ﬁrst chronic phase. Advanced-stage disease was deﬁned as AML
or ALL in second or subsequent relapse or primary induction failure, CML in
blast phase, MDS subtype refractory anemia with excess blasts or in trans-
formation, orMDS not otherwise speciﬁed. Transplantation demographics are
shown in Table 1. The median follow-up was 11.1 years (range, .8 to 22).
Transplantations were facilitated through the National Marrow Donor
Program (NMDP) and performed between 1988 and 2004. Data collection
and analysis were performed under the auspices of the Center for Interna-
tional Blood and Marrow Transplant Research (CIBMTR). Pretransplantdonor and patient research samples were provided by the NMDP/CIBMTR
Research Repository.
Observational studies conducted by the CIBMTR are performed in
compliance with the privacy rule (Health Insurance Portability and
Accountability Act, or HIPAA) as a Public Health Authority and in compliance
with all applicable federal regulations pertaining to the protection of human
research participants as determined by continuous review of the Institu-
tional Review Boards of the NMDP. A standardized modeling process was
used, as previously described [24], to adjust for any bias introduced by the
exclusion of nonconsenting survivors in the NMDP cohort.
Genotyping
SNPs were genotyped using a previously developed in-house assay [25]
based on representative SNPs for TLR1-10. SNPs where selected randomly
among primarily amino acid changing SNPs but also potentially regulatory
SNPs (eg, promoter, 30 untranslated region) and SNPswith previously reported
functional effects from the dbSNP database [26] at the time of assay develop-
ment. Twenty-nine biallelic SNPs observed in persons of European ancestry
were included in the analyses (Supplemental Table S1). Brieﬂy, allele-speciﬁc
primers were labeled in an allele-speciﬁc primer extension reaction, using
PCR-ampliﬁed SNP sites as their target sequences. The labeled allele-speciﬁc
primer extension primers were subsequently hybridized to MicroPlex-xTAG
beadsets (Luminex Corporation, Austin, TX) for detection and counting on
the Luminex platform (Luminex Corporation). All genotypings were carried
out randomized and blinded to the technician performing the genotyping.
Statistics
Probability of leukemia-free survival and overall survival (OS) were
calculated using the Kaplan-Meier estimator. Cumulative incidences were
estimated for other endpoints to accommodate competing risks. Compari-
son of survival curves was done using the log-rank test.
Multivariate analyses were performed using Cox proportional hazards
models, which model the hazard functions for OS and disease-free survival
(DFS) as well as the cause-speciﬁc hazards for competing risks, such as
treatment-related mortality (TRM), relapse, acute GVHD, and chronic GVHD.
All clinical variables were tested for proportional hazards assumptions using
time-dependent covariate approach. Factors violating the proportional
hazards assumption were adjusted through stratiﬁcation. Stepwise model-
building procedures were performed to select the adjusted variables at
the .05 signiﬁcance level for both entry and retaining in the models. Each
SNP was tested for association with the clinical outcomes by forcing it into
the model with the selected adjusted variable.
The multivariate models are shown in Supplemental Table S2. Only 23
SNPs with minor allele frequencies 5% were included in the statistical
analyses. Based on the Bonferroni criterion (23 SNPs for both patients and
donors; .05/46), P  .001 was used for statistical signiﬁcance to adjust for
multiple testing. All analyses were performed using SAS version 9.3 (SAS
Institute, Cary, NC).
RESULTS
Genotyping
The Hardy-Weinberg equilibrium and genotype distri-
butions were analyzed separately for patients and donors
(Supplemental Table S1). All SNPs adhered to the Hardy-
Weinberg equilibrium expectations at the P ¼ .001 level.
Six SNPs (rs3923647 in TLR1, rs5743704 in TLR2, rs5743813
in TLR6, rs5743781 in TLR7, and rs4129008 and rs466657 in
TLR10) were excluded from further analyses because of minor
allele frequencies <5%. Of the remaining 23 SNPs, only TLR8
rs3764879 donor type showed a signiﬁcant association be-
tween genotype and outcome at the P  .001 level in the
multivariate models (Table 2) (Supplemental Table S3).
Association between Donor TLR8 rs3764879 Genotype
and Outcome
Eight hundred two donors were successfully genotyped
for rs3764879, which is located on chromosome X. The mi-
nor allele frequency was 25% both among male and female
donors. Because TLR8 is located on the X chromosome, male
donors can only be hemizygous for a TLR8 gene and therefore
only present 2 genotypes, namely presence or absence of the
major allele. Of 508 male donors, 383 (75%) were hemizy-
gous for the rs3764879 major allele, whereas 125 (25%) were
Table 2
Association between TLR8 rs3764879 Donor Genotype and Outcome
Variable Male Only Female Only
Genotype n HR (95% CI) P Genotype n HR (95% CI) P
OS A 378 1.00 AA 158 1.00
a 124 1.41 (1.09-1.83) .01 Aa 121 1.13 (.83-1.53) .455
aa 13 2.78 (1.43-5.41) .003
DFS A 375 1.00 AA 158 1.00
a 122 1.45 (1.12-1.87) .005 Aa 120 1.23 (.91-1.68) .188
aa 12 2.34 (1.18-4.65) .015
Relapse A 375 1.00 AA 158 1.000
a 122 1.35 (.86-2.12) .193 Aa 120 1.03 (.55-1.91) .935
aa 12 .87 (.20-3.83) .849
TRM A 145 1.00 AA 158 1.00
a 58 1.49 (1.09-2.04) .012 Aa 120 1.21 (.86-1.71) .280
aa 12 3.12 (1.44-6.74) .004
aGVHD
Grades II-IV A 374 1.00 AA 158 1.00
a 123 .89 (.67-1.19) .427 Aa 118 1.16 (.83-1.61) .379
aa 13 1.27 (.61-2.65) .529
Grades III-IV A 367 1.00 AA 148 1.00
a 121 .81 (.51-1.27) .357 Aa 114 1.76 (1.04-2.98) .036
aa 13 3.96 (1.57-9.96) .004
cGVHD A 371 1.00 AA 156 1.00
a 123 1.05 (.79-1.41) .718 Aa 120 .99 (.72-1.36) .965
aa 13 1.22 (.43-3.50) .709
A indicates major allele hemizygous; AA, major allele homozygous; a, minor allele hemizygous; Aa, heterozygous; aa, minor allele homozygous; aGVHD, acute
GVHD; cGVHD, chronic GVHD.
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(54%) were homozygous for the major allele, 122 (42%) were
heterozygous for the minor allele, and 13 (4%) were homo-
zygous for the minor allele.
In the multivariate analyses, male donor hemizygosity
and female donor homozygosity for the rs3764879 minor
allele was an independent risk factor signiﬁcantly associated
with DFS (hazard ratio [HR], 1.47 [95% conﬁdence interval
{CI}, 1.16 to 1.85]; P ¼ .001), which translated into trends
toward lower OS (HR, 1.44 [95% CI, 1.14 to 1.82], P ¼ .002) and
increased TRM (HR, 1.59 [95% CI, 1.19 to 2.12], P ¼ .002)
(Supplemental Table S3). There were no signiﬁcant associa-
tions between rs3764879 genotype and relapse or GVHD
(Supplemental Table S3).
Because of the location of TLR8 on the X chromosome, the
multivariate analyses of the whole cohort were confounded
by the minor allele disparity conferred by gender. When
male and female donor rs3764879 genotypes were analyzed
separately, results were similar to the whole cohort (Table 2).
Although not signiﬁcant at the Bonferroni-corrected P  .001
level, both male donor hemizygosity and female donor ho-
mozygosity for the minor allele were associated with OS
(male donor: HR, 1.41 [95% CI, 1.09 to 1.83], P ¼ .010; female
donor: HR, 2.78 [95% CI, 1.43 to 5.41], P ¼ .003), DFS (male
donor: HR, 1.45 [95% CI, 1.12 to 1.87], P ¼ .005; female donor:
HR, 2.34 [95% CI, 1.18 to 4.65], P ¼ .015), and TRM (male
donor: HR, 1.49 [95% CI, 1.09 to 2.04], P ¼ .012; female donor:
HR, 3.12 [95% CI,1.44 to 6.74], P¼ .004) (Table 2 and Figure 1).
Causes of death are shown in detail in Table 3. Thirty-four
percent of patients transplanted with a male donor hemi-
zygous for the minor allele died of causes unrelated to
relapse or GVHD, namely interstitial pneumonia, infection, or
organ failure, whereas only 27% of patients transplantedwith
a donor hemizygous for the major allele died of these causes
(P ¼ .64). In the group of patients transplanted with a female
donor homozygous for the minor allele, heterozygous for the
major allele, or homozygous for the major allele, 39%, 33%,
and 28% (P ¼ .68), respectively, died of interstitial pneu-
monia, infection, or organ failure.No associations between genotype and relapse or GVHD
were observed. The completemultivariate analyses including
all covariates are shown in Supplemental Table S4. Of note,
data from female donors should be interpreted cautiously
because the number of female donors homozygous for the
minor allele was low (Table 2).
TLR1, TLR4, TLR6, and TLR9 SNPs Previously associated
with Outcome in Allogeneic HCT
Heterozygosity for the TLR4 SNP rs4986790 was previ-
ously associated with hemorrhagic cystitis and invasive
aspergillosis [23,27,28]. Because of low numbers of homo-
zygousminor allele carriers in both patient (n¼ 1) and donor
(n ¼ 3) cohorts, these were included in the group of
heterozygotes for analysis. Patient minor allele carriage of
the TLR4 rs4986790 SNP tended to be associated with
increased risk of TRM (HR,1.15 [95% CI,1.12 to 2.04], P¼ .007),
translating into lower DFS (HR, 1.36 [95% CI, 1.05 to 1.77], P ¼
.0214) and OS (HR, 1.42 [95% CI, 1.09 to 1.86], P ¼ .010)
(Table 4). There were no associations between the rs4986790
genotype and relapse or GVHD.
For TLR1 SNP rs5743611 which was previously associated
with invasive aspergillosis, our data were suggestive of an
association between patient heterozygosity and grades III to
IV acute GVHD (HR, 1.55 [95% CI, 1.05 to 2.29], P ¼ .026), with
no impact on survival (Table 4). In contrast to previous re-
ports, no signiﬁcant associations between the TLR6 SNP
rs5743810 [29] or the TLR9 SNP rs187084 [30] and outcome
were observed (Table 4). Of note, none of the previously
investigated SNPs described in this section was signiﬁcantly
associated with outcome in the current study because the
level for statistical signiﬁcance was set at the conservative
Bonferroni-corrected P  .001.
DISCUSSION
The current study is the largest investigation of associa-
tions between TLR SNPs and outcome after allogeneic HCT at
present. Our cohort of 816 patient and donor pairs was
genotyped for 29 SNPs across the 10 known human TLR
Figure 1. Adjusted probability of OS, DFS, and TRM according donor TLR8 rs3764879 genotype analyzed separately for male (A, B, and C, respectively) and female
donors (D, E, and F, respectively). A/-, major allele hemizygous (solid line); a/-, minor allele hemizygous (dashed line); A/A, major allele homozygous (solid line); A/a,
heterozygous (dotted line); a/a, minor allele homozygous (dashed line).
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nor allele frequencies<5% were excluded, leaving 23 SNPs to
be tested in the multivariate models for clinical outcome
variables. Although conservative, the Bonferroni methodwas
used to adjust for multiple comparisons to lower the risk of
false-positive associations. Because TLR8 is located on the X
chromosome and males only carry one of these, they can
only present phenotypes corresponding to either major or
minor allele homozygosity, whereas heterozygosity also ex-
ists in the female population.
Hemi- or homozygosity for the rs3764879 minor allele in
male and female donors was signiﬁcantly associated with
lower DFS with trends toward lower OS and TRM. No asso-
ciation with GVHD or relapse was observed. Although the
rs3764879 genotype is inherently confounded by gender, no
interactions between gender and genotype were observed.
When male and female donors were analyzed separately,
patterns similar to that seen in the whole cohort were
observed, but levels of signiﬁcance were lower in the sepa-
rate male and female donor subsets, in line with the reducedpower of the stratiﬁed analyses. Especially in the female
subset, data should be interpreted with caution because of
low numbers of minor allele homozygous donors. However,
data do suggest a clinical impact of the absence of pheno-
typical expression of the rs3764879 major allele.
No associations were observed between rs3764879 and
relapse or GVHD, indicating that the poorer outcome was
conferred by other causes. Although not signiﬁcant, we did
observe higher frequencies of death related to interstitial
pneumonia, infection, or organ failure. The ﬁnding is in line
with TLR8 being part of the antiviral immune responsewhere
it recognizes non-self nucleic acids and subsequently stim-
ulates the release of pro-inﬂammatory cytokines [31]. The
rs3764879 SNP is located in the promoter region of TLR8, and
the minor allele has been associated with lower cytokine
production [32]. TLR8 is expressed mainly by hematopoieti-
cally derived cells (monocytes and myeloid-derived den-
dritic cells) [33,34], and in keeping with this, the signiﬁcant
associations between outcomes and genotypes were not
found for recipient genotypes of the TLR8 SNP.
Table 3
Causes of Death according to TLR8 rs3764879 Donor Genotype
Cause of Death Male Donors Female Donors
Genotype n (%) P Genotype n (%) P
Primary disease A/- 40 (10) .76 AA 17 (11) .37
a/- 17 (14) Aa 8 (7)
aa 1 (8)
New malignancy A/- 5 (1) .53 AA 1 (1) .92
a/- 1 (1) Aa 1 (1)
aa 0 (0)
GVHD A/- 29 (8) .91 AA 17 (11) .72
a/- 11 (9) Aa 10 (8)
aa 2 (15)
Interstitial
pneumonia
A/- 21 (6) .41 AA 16 (16) .74
a/- 11 (9) Aa 16 (13)
aa 2 (15)
Infection A/- 45 (12) .77 AA 20 (13) .44
a/- 19 (15) Aa 10 (8)
aa 2 (15)
Organ failure A/- 37 (10) .70 AA 9 (6) .19
a/- 13 (10) Aa 14 (12)
aa 1 (8)
Other A/- 29 (8) .50 AA 16 (10) .58
a/- 9 (7) Aa 16 (13)
aa 3 (23)
A/- indicates hemozygus for the major allele; a/-, hemozygous for the minor
allele; AA, homozygous for the major allele; Aa heterozygous; aa, homo-
zygous for the minor allele.
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codon 1 TLR8 SNP rs3764880, which introduces a frame-shift
mutation leading to a truncated ﬁnal protein [35,36]. Only a
few studies have addressed the association between TLR8 ge-
notype and disease, and in agreementwith our data, they have
shown associations between the minor allele of the promoter
SNP (rs3764879) or the codon 1 SNP (rs3764880) and pro-
gression of HIV infection, susceptibility to mycobacterium
tuberculosis, hepatitis C infection, and asthma [36-40].
Several polymorphisms across most TLRs have been
studied in a variety of disease settings [41]. The most
extensively investigated are the functional nonsynonymous
TLR4 SNPs D299G (rs4986790) and T399I (rs4986791), which
are in linkage disequilibrium [21]. TLR4 recognizes microbial
cell wall components from gram-negative bacteria and
fungal ligands such as candida mannan, glucuronox-
ylomannan, and Aspergillus fumigatus antigens [9,42,43]. In
the setting of allogeneic HCT, both D299G and T399I have
been associated with invasive aspergillosis. Koldehoff et al.
[27] observed that patient or donor carriage of the minor
allele of either SNP was associated with invasive aspergil-
losis, whereas Bochud et al. [21] in a large discovery/valida-
tion cohort observed a signiﬁcant association between donor
carriage of the minor allele and invasive aspergillosis and
TRM. In contrast, Kesh et al. [29] did not observe an associ-
ation between TLR4 D299G and T399I genotype and invasive
aspergillosis. The same study also included SNPs in TLR1 and
TLR6 that heterodimerize with TLR2 to mediate responses to
lipopeptides from several pathogens. Presence of either the
minor allele of TLR1 (rs5743611) or TLR1 (rs4833095) and
TLR6 (rs5743810) in the recipient was associated with
increased risk of invasive aspergillosis [29].
Presence of theminor allele of TLR4D299G in both patient
and donor has also been associatedwith hemorrhagic cystitis
in a pediatric cohort transplanted after myeloablative con-
ditioning [23]. Elmaagacli et al. [30] investigated 2 SNPs in
TLR9, which is located intracellularly and senses single-
stranded DNA from microbial pathogens containing CpG
motifs, in a cohort of AML patients treated with high-doseallogeneic HCT. They observed that patient homozygosity
for rs187084 conferred a lower 5-year probability of relapse
and increased OS.
None of the previously published associations between
TLR genotypes and allogeneic HCT was replicated at the
Bonferroni-adjusted signiﬁcance level of P  .001. However,
in the current study, patient carriage of the TLR4 SNP
rs4986790 minor allele was associated with TRM and OS at
the P< .05 level, lending support to the probable importance
of TLR4 genotype on infection-related morbidity and mor-
tality. In contrast to previous reports, no association between
D299G and acute GVHD were observed [20,28] and no rele-
vant signiﬁcant associations between previously studied
SNPs in TLR1, TLR6, and TLR9 were observed [29,30].
The inconsistent results often observed across genetic
association studies are due to several factors that make direct
interstudy comparisons difﬁcult. The generally small cohorts
in transplant studies increase the risk of Type I errors
because the effect of single genetic variants usually is
modest. Furthermore, heterogeneity between patient pop-
ulations, with differences in treatment regimens, diagnoses,
racial admixture, other yet unknown risk factors, and the
possibility of the selected polymorphisms being in linkage
disequilibriumwith unknown functional polymorphisms, all
contribute to an unclear picture.
In conclusion, the present study is currently the largest
and most comprehensive investigation of associations be-
tween TLR genotype and outcome after allogeneic HCT.
Although none of the previously published associations
between TLR SNPs and outcome were validated at the
Bonferroni-corrected signiﬁcance level, similar trends were
observed. However, a novel association between a TLR8
promoter polymorphism and survival was observed, and
evidence supporting the importance of TLR4 D299G was
presented. To conﬁrm the signiﬁcance of these ﬁndings,
further experimental and clinical studies are needed to
explain their molecular background and assess their impact
on outcome in a prospective manner, respectively.
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P n Patient TLR6 (rs5743810)
HR (95% CI)
P n Patient TLR9 (rs187084)
HR (95% CI)
P
OS 703 1.000 247 1.000 278 1.000
102 1.204 (.928-1.562) .163 409 1.073 (.871-1.321) .510 386 .877 (.716-1.073) .202
0 NA NA 136 1.065 (.810-1.401) .652 128 .920 (.700-1.208) .549
DFS 697 1.000 245 1.000 274 1.000
101 1.205 (.935-1.554) .150 404 1.039 (.846-1.275) .716 385 .865 (.709-1.056) .153
0 NA NA 136 1.052 (.804-1.376) .711 126 .927 (.709-1.211) .580
Relapse 697 1.000 245 1.000 274 1.000
101 .734 (.428-1.260) .262 404 .705 (.484-1.028) .069 385 .761 (.531-1.093) .139
0 NA NA 136 .978 (.614-1.557) .925 126 0.622 (.360-1.073) .088
TRM 697 1.000 245 1.000 274 1.000
101 1.388 (1.040-1.854) .026 404 1.188 (.929-1.518) .169 385 .961 (.758-1.220) .746
0 NA NA 136 1.032 (.744-1.431) .851 126 1.061 (.779-1.444) .709
aGVHD 698 1.000 244 1.000 275 1.000
Grades II-IV 99 1.018 (.764-1.358) .901 407 .988 (.797-1.224) .912 283 .982 (.792-1.217) .865
0 NA NA 134 .812 (.603-1.092) .168 127 (.889-1.555) .258
676 1.000 239 1.000 270 1.000
Grades III-IV 98 1.286 (.849-1.946) .235 395 .862 (.620-1.198) 369 .809 (.579-1.128) .212
0 NA NA 128 .809 (.512-1.278) 123 1.071 (.712-1.613) .741
687 1.000 244 1.000 271 1.000
cGVHD 99 1.089 (.806-1.470) .580 395 .973 (.785-1.207) .805 378 1.128 (.909-1.400) .275
0 NA NA 135 .791 (.586-1.067) .125 125 1.193 (.898-1.585) .223
rs number indicates reference SNP number; NA, not available.
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